Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report by Annemarie Gawehn et al.
CASE REPORT Open Access
Successful thrombolysis with recombinant
tissue plasminogen activator after
antagonizing dabigatran by idarucizumab:
a case report
Annemarie Gawehn1,2, Yassine Ayari1,2, Christian Heuschkel1,2, Matthias Kaste1,2 and Pawel Kermer1,2*
Abstract
Background: Effective anticoagulation routinely precludes patients from receiving intravenous thrombolysis with
recombinant tissue plasminogen activator to reverse severe symptoms of ischemic stroke. We report what we
believe to be the first case of ischemic stroke successfully treated with recombinant tissue plasminogen activator
after antagonizing dabigatran with the monoclonal antibody idarucizumab, recently approved worldwide.
Case presentation: A 75-year-old Caucasian man presented to our hospital with severe aphasia and mild hemiparesis.
After providing written consent, he received two doses of 2.5 g of idarucizumab over 20 minutes followed by standard
protocol in-label recombinant tissue plasminogen activator application. All symptoms resolved within 1 h.
Conclusions: Applying a recombinant tissue plasminogen activator after antagonizing dabigatran with idarucizumab is feasible
and easy to manage in an emergency room or stroke unit. Thus, idarucizumab represents a new therapeutic option for patients
receiving dabigatran treatment, reestablishing their eligibility for recombinant tissue plasminogen activator thrombolysis.
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Background
Neurologists have used dabigatran mostly for secondary pre-
vention of cardioembolic stroke in patients with atrial fibril-
lation since the phase III RE-LY trial [1] showed positive
results for the prevention of stroke or systemic embolism as
compared with warfarin. Besides dabigatran, three additional
non-vitamin-K-dependent oral anticoagulants (NOACs) [2–
4] are currently available. Substantially decreased rates of
bleeding complications in comparison with warfarin, espe-
cially when considering intracerebral hemorrhage, are an ad-
vantage of NOAC therapy. However, one major concern
was the lack of specific antidotes. With the approval of idar-
ucizumab, a novel monoclonal antibody fragment with a
high potency to reverse the anticoagulant effects of dabiga-
tran within minutes [5, 6], the question arose if recombinant
tissue plasminogen activator (rt-PA) could be used after
reversal of dabigatran with idarucizumab in individuals with
newly occurring ischemic stroke. Since the introduction of
NOAC therapy, these patients have frequently been ex-
cluded from thrombolytic therapy, owing to the unpredict-
able risk of bleeding.
Case presentation
A 75-year-old, right-handed Caucasian man with a history
of embolic stroke and atrial fibrillation was admitted on 30
January 2016 to the stroke unit of our primary care hospital
for severe aphasia and right-sided hemiparesis with sudden
onset of symptoms about 1 h before presentation. He was
receiving NOAC therapy with dabigatran 110 mg twice
daily. His CHA2DS2-VASc score was 6 points (on scale
representing congestive heart failure [or left ventricular sys-
tolic dysfunction] 1 point, hypertension [blood pressure con-
sistently above 140/90 mmHg or treated hypertension on
medication] 1 point, age ≥75 years 2 points, diabetes melli-
tus 1 point, prior stroke or transient ischemic attack or
thromboembolism 2 points, vascular disease [e.g., peripheral
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artery disease, myocardial infarction, aortic plaque] 1 point,
age 65–74 years 1 point, sex category [female sex] 1 point),
and his HAS-BLED score was 3 points (with scale repre-
senting hypertension, abnormal renal and liver function,
stroke, bleeding, labile international normalized ratio, eld-
erly, drugs or alcohol). Correct dabigatran therapy of
110 mg twice daily could be verified by the accompanying
spouse with last intake on the same morning approximately
9.5 h before. Besides cardioembolic stroke, the patient’s
medical history consisted of structural epilepsy based on
middle cerebral artery ischemia in March 2015 treated with
levetiracetam 500 mg twice daily and arterial hypertension
treated with amlodipine, metoprolol, and torasemide.
The patient’s impairment of production and comprehen-
sion of speech was severe. It was possible for him to com-
municate, but only to a very limited extent. His hemiparesis
was rather mild. His initial National Institutes of Health
Stroke Scale (NIHSS) score was 5. No convulsions or lack
of consciousness was reported or noticed. According to the
patient’s spouse, his symptoms were not comparable to
prior seizure symptomatology displayed by sudden loss of
consciousness and generalized tonic-clonic convulsions. As
a residual of his prior stroke, the patient had a slight outer
rotation of his right foot without gait impairment.
Laboratory examinations done upon admission revealed
a slight coagulation disorder (international normalized ratio
1.01, activated partial thromboplastin time [aPTT] 39.0 sec-
onds [upper limit of normal 42 seconds], thrombin time
66.8 seconds [upper limit of normal 22 seconds]). Besides a
defect zone arising from ischemic stroke in May 2015,
computed tomographic (CT) scans (Fig. 1) displayed no
early signs of acute stroke. Taking into account the patient’s
NIHSS score of 5, no CTangiography or perfusion protocol
was performed, in accordance with effective stroke guide-
lines. Except for the existing oral dabigatran anticoagulation
therapy, the patient’s history did not reveal any contraindi-
cations against systemic thrombolytic therapy. After the pa-
tient provided written consent, we applied two doses of
2.5 g idarucizumab according to the current product char-
acteristics and prescribing information within 20 minutes
to antagonize dabigatran. Another blood sample showing
normalized coagulation parameters preceded immediate
weight-adapted intravenous rt-PA therapy. Within 1 h, all
symptoms resolved to baseline levels.
A clinical examination done the next day revealed fluent
speech with hardly noticeable word-finding difficulties in
an aphasia assessment. Detailed conversation was possible
again, and the patient reported subjective well-being. Be-
cause the patient’s symptoms resolved within 1 h and be-
cause of the lack of therapeutic consequences, we abstained
from follow-up magnetic resonance imaging scans as part
of the stroke workup. The patient’s electroencephalogram
was free of any epileptic discharges. Echocardiography re-
vealed no evidence of intracardial thrombotic material, and
an ultrasound of the brain-supplying arteries did not reveal
relevant stenoses. With the patient’s low-density lipoprotein
cholesterol values being elevated (160 mg/dl), we initiated
therapy with simvastatin 20 mg. Dabigatran therapy was
reestablished after 24 h. However, on the basis of the pa-
tient’s age and normal renal function, we chose an in-
creased dose of 150 mg twice daily according to the
effective prescribing information. During idarucizumab ap-
plication and throughout the entire hospital stay, no throm-
botic or bleeding complications occurred. The patient’s
laboratory examination results remained normal, and he
was released to home in good health.
Discussion
Intravenous rt-PA thrombolysis in acute ischemic stroke is
considered an emergency intervention allowing an in-label
Fig. 1 Computed tomographic scan taken upon admission shows no early signs of acute stroke, but displays the residuals of a cardioembolic
stroke in the left hemisphere that had occurred in May 2015
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application of idarucizumab. Interestingly, in our patient,
thrombin time was the only clearly pathologic coagulation
parameter 9.5 h after the last medication intake. aPTT was
somehow prolonged but still within normal range. A
second laboratory examination done immediately after idar-
ucizumab application showed normal coagulation parame-
ters. This allowed in-label use of rt-PA, which is prohibited
when anticoagulation therapy is in effect. However, we did
not wait for the results, but rather infused rt-PA in order
not to lose time to reperfusion of ischemic brain regions. In
cases where the second laboratory examinations still show
prolonged thrombin time, we suggest immediate termin-
ation of rt-PA infusion. However, according to the available
idarucizumab data, dabigatran anticoagulation should be
abrogated in more than 98 % of patients [6]. Besides our
patient, two similar cases [7, 8] have recently been reported.
In both cases, rt-PA could be administered successfully
after reversing anticoagulation effects of dabigatran by
using the specific antidote idarucizumab. As for our patient,
no adverse events such as thromboembolism or bleeding
occurred in these two cases. Still, large registries on the use
of idarucizumab should be established with special em-
phasis on unfavorable outcomes such as thrombotic events,
bleeding, and mortality to further explore potential con-
cerns regarding safety and efficacy.
Conclusions
To our knowledge, and according to available supplier in-
formation, we report the first case worldwide of ischemic
stroke successfully treated with rt-PA after antagonizing
dabigatran with idarucizumab. In line with two other recent
German cases, in which the procedure appeared to be feas-
ible, easy to manage, and without severe adverse events,
this novel therapeutic option should be considered in indi-
viduals presenting with ischemic stroke who are receiving
dabigatran therapy. However, further evidence concerning
safety and efficacy is needed before this therapeutic regimen
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